object
aim
studi
clarifi
clinic
characterist
predict
mortal
risk
among
patient
viral
pneumonia
method
total
patient
viral
pneumonia
ruijin
hospit
shanghai
may
may
recruit
multiplex
realtim
rtpcr
use
detect
respiratori
virus
demograph
inform
comorbid
routin
laboratori
examin
immunolog
index
etiolog
detect
radiolog
imag
treatment
collect
admiss
result
patient
die
within
day
hospit
predict
mulbsta
score
calcul
basi
multivari
logist
regress
model
order
predict
mortal
weight
score
includ
multilobular
infiltr
ci
p
point
lymphocyt
l
ci
p
point
bacteri
coinfect
ci
p
point
acutesmok
ci
p
point
quitsmok
ci
p
point
hypertens
ci
p
point
age
year
ci
p
point
point
use
cutoff
valu
mortal
risk
stratif
model
show
sensit
specif
better
predict
abil
auroc
vs
p
conclus
design
easytous
clinic
predict
tool
assess
mortal
risk
viral
pneumonia
accur
stratifi
hospit
patient
viral
pneumonia
relev
risk
categori
could
provid
guidanc
make
clinic
decis
statement
viral
infect
could
present
sever
pneumonia
acut
respiratori
distress
syndrom
complic
bacteri
superinfect
mani
patient
influenza
respiratori
virus
common
reason
acut
pneumonia
result
signific
morbid
mortal
set
highrisk
factor
extrem
age
pregnanc
obes
chronic
preexist
condit
cytokin
chemokin
hand
regard
possibl
hallmark
sever
diseas
mani
reach
high
serum
level
set
sever
infect
although
varieti
clinic
predict
rule
pneumonia
wide
use
assess
commun
acquir
pneumonia
standard
rule
calcul
viral
pneumonia
sever
score
establish
knowledg
design
easytous
clinic
predict
score
assess
mortal
risk
viral
pneumonia
model
show
better
predict
abil
cindex
sensit
specif
cutoff
valu
point
could
use
mortal
risk
stratif
background
viral
infect
spite
common
manifest
mild
ill
present
sever
pneumonia
acut
respiratori
distress
syndrom
ard
bacteri
coinfect
mani
patient
shorr
et
al
recent
year
dissemin
pcr
increas
abil
detect
respiratori
virus
upper
lowerrespiratori
tract
sampl
da
et
al
influenza
respiratori
virus
common
reason
acut
respiratori
infect
patient
predispos
bacteri
infect
greater
morbid
mortal
level
hanada
et
al
natur
infect
adapt
innat
immun
respons
play
import
role
control
respiratori
viru
infect
nuss
et
al
adapt
b
cell
maintain
immunolog
memori
provid
protect
subsequ
viru
infect
cytokin
chemokin
hand
regard
possibl
hallmark
sever
diseas
mani
reach
high
serum
level
set
sever
infect
la
gruta
et
al
variabl
also
could
guid
clinic
decis
make
well
infecti
diseas
manag
although
varieti
clinic
predict
rule
pneumonia
wide
use
assess
commun
acquir
pneumonia
cap
viasu
et
al
uranga
et
al
remain
applic
set
viral
infect
report
risk
factor
influenza
pneumonia
lymphocyt
count
antigenspecif
cell
likewis
use
predict
mortal
decid
appropri
manag
viasu
et
al
shi
et
al
knowledg
standard
rule
calcul
viral
pneumonia
sever
score
establish
aim
elucid
potenti
risk
factor
attempt
predict
probabl
mortal
among
patient
infect
respiratori
virus
retrospect
singlecent
observ
studi
conduct
may
may
ruijin
hospit
shanghai
china
studi
approv
ruijin
hospit
ethic
committe
written
inform
consent
obtain
patient
involv
enrol
retrospect
studi
hospit
patient
posit
result
multiplex
realtim
reversetranscript
polymeras
chain
reaction
rtpcr
tib
respiratori
kit
roch
switzerland
aim
detect
respiratori
virus
time
period
studi
select
introduct
viral
test
panel
patient
diagnos
pneumonia
accord
infecti
diseas
societi
american
idsa
american
thorac
societi
at
guidelin
charl
et
al
enrol
studi
patient
exclud
age
year
clear
altern
final
diagnosi
lung
cancer
nonpneumonia
ill
long
hospit
month
death
hospit
patient
initi
posit
rtpcr
result
enrol
pneumonia
total
case
exclud
final
diagnosi
nonpneumonia
ill
n
children
adolesc
patient
n
pneumonia
patient
posit
viral
detect
final
includ
analysi
figur
infect
due
influenza
flua
adenoviru
adv
bocaviru
human
rhinoviru
hrv
influenza
b
flub
parainfluenza
piv
coronaviru
cov
respiratori
syncyti
viru
rsva
respiratori
syncyti
viru
b
rsvb
enteroviru
ev
human
metapneumoviru
hmpv
confirm
use
rtpcr
via
nasal
wash
product
data
collect
admiss
includ
demograph
inform
comorbid
routin
laboratori
examin
chest
radiographi
ct
scan
immunolog
etiolog
detect
use
posit
bacteri
cultur
blood
sputum
sampl
criteria
bacteri
growth
use
antivir
therapi
steroid
record
includ
drug
start
date
durat
dosag
patient
evalu
deem
clinic
appropri
time
pneumonia
suspect
score
patient
calcul
barlow
et
al
length
stay
outcom
state
patient
record
improv
patient
hospit
stay
day
follow
phone
call
determin
surviv
statu
seen
outpati
clinic
final
outcom
mortal
defin
overal
mortal
within
day
viral
pneumonia
patient
classifi
two
group
surviv
group
death
group
univari
analysi
initi
use
compar
risk
factor
mortal
separ
among
patient
viral
pneumonia
proport
mean
sd
use
character
patient
sampl
continu
variabl
compar
use
ttest
oneway
anova
fisher
exact
test
use
categor
depend
data
analysi
appropri
percentag
miss
valu
variabl
cohort
lower
imput
miss
data
covari
use
multipl
imput
stern
et
al
conclus
univari
logist
regress
analys
without
imput
data
unchang
continu
variabl
categor
retain
multivari
test
cutoff
point
identifi
follow
youden
index
receiv
oper
characterist
roc
curv
clinic
relev
cutoff
variabl
p
regard
potenti
risk
factor
includ
multivari
regress
analysi
overal
mortal
reduc
backward
elimin
procedur
condit
likelihood
ratio
test
elimin
p
data
patient
partit
randomli
two
complementari
subset
train
set
use
establish
model
test
set
use
valid
analysi
pragmat
reason
score
predictor
assign
integ
valu
rel
regress
coeffici
cutoff
point
identifi
follow
youden
index
roc
surviv
analysi
perform
use
univari
approach
kaplanmei
analysi
lowrisk
highrisk
group
accord
cutoff
valu
perform
score
assess
measur
area
roc
curv
auroc
sensit
specif
calcul
intern
valid
assess
auroc
bootstrap
sampl
crossvalid
assess
calcul
auroc
test
set
roc
curv
net
reclassif
improv
nri
leen
et
al
analys
use
assess
improv
risk
predict
capac
compar
statist
analysi
perform
use
spss
version
r
test
twosid
pvalu
consid
signific
baselin
characterist
complet
case
differ
group
describ
tabl
mean
age
viral
pneumonia
patient
sd
year
male
immun
examin
surviv
dead
patient
describ
tabl
lower
serum
level
tlymphocyt
subtyp
note
death
group
p
moreov
patient
death
group
found
possess
lower
serum
level
tlymphocyt
subtyp
p
elev
level
cytokin
p
p
p
analyz
immunolog
indic
patient
subgroup
without
bacteri
infect
lower
level
p
p
p
tlymphocyt
count
found
group
suffer
bacteri
infect
interleukin
elev
level
cytokin
p
p
p
also
found
bacteri
group
statist
signific
differ
comparison
figur
compar
score
sever
prognos
among
patient
without
bacteri
coinfect
tabl
patient
bacteri
infect
reveal
strike
differ
score
use
either
noninvas
invas
ventil
icu
admiss
rate
length
hospit
treatment
cost
compar
simpli
suffer
viral
infect
multipl
imput
miss
data
perform
serum
interleukin
miss
miss
lymphocyt
subset
level
miss
bodi
mass
index
bmi
lymphocyt
count
miss
accord
method
analys
follow
categor
variabl
enter
backward
stepwis
logist
regress
analysi
male
age
year
smoke
histori
hypertens
lymphocyt
l
posit
sputum
sanguin
cultur
bacteria
fungi
infect
multilobular
infiltr
tabl
order
develop
simpl
use
clinic
predict
tool
rel
weight
assign
accord
regress
coeffici
categor
variabl
figur
show
coeffici
odd
ratio
ci
calcul
multilobular
infiltr
hypolymphocytosi
bacteri
coinfect
smoke
histori
hypertens
age
mulbsta
score
auroc
train
set
ci
auroc
test
set
ci
total
patient
auroc
ci
sensit
specif
correspond
risk
death
mulbsta
shown
tabl
patient
divid
highrisk
lowrisk
group
consid
cutoff
valu
kaplanmei
surviv
curv
highrisk
lowrisk
group
shown
figur
continu
paramet
present
mean
sd
categor
data
n
comparison
nomogram
full
regress
model
origin
form
shown
supplement
figur
compar
mulbsta
score
differ
auroc
origin
regress
model
vs
p
cohort
mulbsta
significantli
stronger
predictor
overal
mortal
auroc
vs
p
n
figur
averag
auroc
bootstrap
n
mulbsta
model
score
separ
nri
mulbsta
also
improv
nri
ci
p
commonli
use
predict
mortal
also
assess
use
mulbsta
score
mortal
tend
stronger
predictor
auroc
vs
p
n
patient
hospit
viral
pneumonia
simpl
prognost
tool
made
overal
mortal
use
predict
sever
day
admiss
upon
obtain
cultur
result
score
predict
prognos
greater
accuraci
pneumonia
global
caus
death
high
shortterm
longterm
mortal
though
shortterm
mortal
rate
high
acut
diseas
longterm
mortal
within
day
year
year
also
noteworthi
previou
studi
mortensen
et
al
uranga
et
al
nowaday
surviv
time
patient
sever
lung
failur
progress
radiolog
imag
new
drug
support
techniqu
like
extracorpor
membran
oxygen
ecmo
pappalardo
et
al
prospect
research
viral
pneumonia
show
higher
mortal
rate
overal
mortal
length
hospit
stay
day
zhou
et
al
hospit
patient
studi
die
day
hospit
stay
among
live
longer
day
make
mortal
worthi
attent
immun
defici
close
rel
mortal
evalu
immun
condit
could
conduct
monitor
patient
gener
condit
estim
prognosi
studi
tlymphocyt
subtyp
reduc
death
group
reflect
defici
adapt
immun
respons
prior
research
viral
infect
indic
adapt
cell
provid
broader
last
crossreact
cellular
immun
less
limit
strainspecif
restrict
especi
cell
bender
et
al
besid
higher
level
proinflammatori
cytokin
document
attribut
sever
diseas
lung
damag
da
et
al
accordingli
appear
significantli
correl
ill
sever
complement
cell
function
nuss
et
al
present
significantli
higher
serum
level
death
group
also
found
relat
mortal
univari
regress
meanwhil
secret
along
adopt
transfer
cell
clone
associ
delay
viral
clearanc
fail
caus
protect
effect
la
gruta
et
al
although
test
interleukin
yet
wide
avail
suggest
patient
could
stratifi
regard
mortal
risk
bacteri
coinfect
set
viral
pneumonia
known
anoth
major
caus
mortal
acinetobact
baumannii
one
commonli
encount
pathogen
prior
studi
investig
gao
et
al
compar
patient
without
bacteri
infect
bacteri
coinfect
manifest
worsen
outcom
also
prolong
hospit
stay
significantli
increas
cost
hospit
care
bacteri
infect
independ
predictor
without
drive
forc
viral
pneumonia
deterior
bacteri
infect
occur
spontan
process
consid
associ
dysregul
tcell
antigenspecif
cell
plasma
cytokin
level
li
cao
level
inflammatori
cytokin
found
higher
patient
suffer
bacteri
influenza
viru
coinfect
patient
infect
sole
pathogen
li
et
al
remark
increas
patient
coinfect
bacteria
demonstr
predict
potenti
despit
intens
effort
develop
antivir
therapi
prevent
treat
respiratori
viru
infect
limit
influenza
antivir
oseltamivir
zanamivir
commonli
use
basi
intern
recommend
jefferson
et
al
howev
oral
oseltamivir
rel
strict
time
window
sever
secondari
effect
like
nausea
renal
syndrom
hard
use
unconsci
patient
lee
et
al
effect
list
antivir
vaccin
approv
prevent
treatment
noninfluenza
virus
heylen
et
al
studi
oseltamivir
commonli
use
antivir
therapi
acyclovir
ganciclovir
foscarnet
use
cytomegaloviru
herp
simplex
viru
nevertheless
earli
antivir
treatment
prevent
progress
pneumonia
consist
earlier
studi
elizaga
et
al
chemali
et
al
confus
choic
respiratori
viru
therapi
make
urgent
predict
mortal
accur
date
varieti
studi
concern
respiratori
virus
found
demonstr
risk
factor
multivari
regress
consist
previou
report
combin
lymphopenia
peripher
blood
lymphocyt
count
l
report
simpl
reliabl
predictor
influenza
shi
et
al
multilobular
infect
also
note
studi
also
remark
factor
prior
report
jen
et
al
studi
also
statist
signific
mortal
predictor
accord
univari
analysi
cutoff
adjust
moreov
younger
age
chronic
comorbid
condit
morbid
obes
highdos
steroid
use
hematopoiet
stem
cell
therapi
lower
level
specif
cell
lack
earli
antivir
therapi
also
regard
independ
risk
factor
sever
diseas
accord
prior
report
viasu
et
al
chemali
et
al
li
cao
howev
none
signific
studi
idsaat
guidelin
recommend
confus
urea
respiratori
rate
blood
pressur
age
year
one
cap
sever
score
charl
et
al
howev
low
mortal
rate
among
patient
categor
low
risk
mandel
et
al
sever
studi
argu
increas
age
wors
predict
abil
due
fact
influenza
viru
report
occur
younger
individu
riquelm
et
al
bjarnason
et
al
meanwhil
rel
mortal
rate
viru
infecti
diseas
elderli
report
twice
young
pawelec
et
al
earli
studi
suggest
high
cell
count
low
nk
activ
correl
significantli
surviv
infecti
diseas
elderli
ogata
et
al
suggest
age
could
lead
increas
immun
defici
mortal
popul
hospit
viral
pneumonia
patient
age
year
statist
associ
mortal
weight
coeffici
rel
small
reason
complet
deni
import
age
appropri
weight
adjust
may
enhanc
predict
capac
model
paramet
identifi
mulbsta
score
easi
get
clinic
examin
recommend
done
admiss
hospit
roc
nri
analysi
suggest
new
score
better
predict
capac
comparison
moreov
mulbsta
score
show
promis
risk
stratif
patient
hospit
viral
pneumonia
death
rate
grade
tabl
suggest
follow
risk
categori
mulbsta
lowrisk
mortal
mulbsta
highrisk
mortal
higher
mulbsta
score
might
use
good
predictor
prognosi
limit
studi
also
acknowledg
retrospect
singlecent
design
lead
miss
data
unavoid
bias
identifi
recruit
particip
sampl
size
rel
small
order
build
predict
score
despit
limit
studi
design
reflect
real
life
clinic
situat
clinic
inform
meticul
gather
use
standard
protocol
admit
medic
team
score
might
assist
clinician
make
appropri
decis
optim
use
hospit
resourc
found
mulbsta
score
base
six
paramet
routin
avail
hospit
strong
predict
abil
mortal
accur
stratifi
hospit
patient
viral
pneumonia
relev
risk
categori
could
provid
guidanc
make
clinic
decis
dataset
analyz
studi
found
figshar
link
http
figsharecomarticlesdatasetforth
